Biogened S.A. (WSE:BGD)
18.60
+0.50 (2.76%)
At close: Jun 15, 2026
Biogened Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 109.49 | 113.11 | 110.93 | 95.56 | 79.62 | 65.32 | |
Revenue Growth (YoY) | -4.12% | 1.97% | 16.09% | 20.02% | 21.89% | 35.15% |
Cost of Revenue | 38.26 | 41 | 34.28 | 32.07 | 22.18 | 23 |
Gross Profit | 71.23 | 72.11 | 76.65 | 63.49 | 57.44 | 42.32 |
Selling, General & Admin | 61.72 | 63.55 | 66.88 | 54.62 | 41.86 | 35.29 |
Other Operating Expenses | 0.17 | 0.31 | 0.72 | 0.7 | 7.2 | 2.43 |
Operating Expenses | 61.89 | 63.85 | 67.6 | 55.32 | 49.06 | 37.73 |
Operating Income | 9.34 | 8.26 | 9.06 | 8.16 | 8.38 | 4.59 |
Interest Expense | -2.08 | -2.21 | -2.37 | -2.16 | -1.7 | -0.6 |
Interest & Investment Income | - | 0 | 0 | 0 | 0 | 0.01 |
Other Non Operating Income (Expenses) | -0.46 | -0.4 | -0.17 | 0 | -0.32 | -0.16 |
EBT Excluding Unusual Items | 6.81 | 5.65 | 6.52 | 6.01 | 6.36 | 3.84 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.49 |
Gain (Loss) on Sale of Assets | 0.46 | 0.42 | 0.32 | 0.88 | 0.03 | -0 |
Other Unusual Items | - | -0.08 | 0.85 | - | - | - |
Pretax Income | 7.26 | 5.99 | 7.69 | 6.89 | 6.39 | 4.33 |
Income Tax Expense | 2.4 | 1.05 | 1.87 | 1.79 | 3.01 | 2.37 |
Net Income | 4.87 | 4.94 | 5.82 | 5.1 | 3.38 | 1.96 |
Net Income to Common | 4.87 | 4.94 | 5.82 | 5.1 | 3.38 | 1.96 |
Net Income Growth | -19.32% | -15.11% | 14.22% | 50.74% | 72.46% | 57.92% |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 |
EPS (Basic) | 1.98 | 2.01 | 2.37 | 2.08 | 1.38 | 0.80 |
EPS (Diluted) | 1.98 | 2.01 | 2.37 | 2.08 | 1.38 | 0.80 |
EPS Growth | -19.32% | -15.11% | 14.22% | 50.74% | 72.46% | 57.92% |
Free Cash Flow | 3.49 | 5.13 | -1.49 | 7.72 | -3.35 | 1.57 |
Free Cash Flow Per Share | 1.42 | 2.09 | -0.61 | 3.14 | -1.36 | 0.64 |
Dividend Per Share | - | - | 0.500 | 0.500 | 0.400 | - |
Dividend Growth | - | - | - | 25.00% | - | - |
Gross Margin | 65.05% | 63.75% | 69.10% | 66.44% | 72.14% | 64.78% |
Operating Margin | 8.53% | 7.30% | 8.16% | 8.54% | 10.52% | 7.03% |
Profit Margin | 4.45% | 4.37% | 5.25% | 5.33% | 4.25% | 3.00% |
Free Cash Flow Margin | 3.19% | 4.53% | -1.35% | 8.08% | -4.21% | 2.41% |
EBITDA | 13.95 | 12.63 | 13.19 | 11.69 | 11.31 | 7.47 |
EBITDA Margin | 12.74% | 11.17% | 11.89% | 12.23% | 14.21% | 11.44% |
D&A For EBITDA | 4.61 | 4.37 | 4.13 | 3.52 | 2.94 | 2.88 |
EBIT | 9.34 | 8.26 | 9.06 | 8.16 | 8.38 | 4.59 |
EBIT Margin | 8.53% | 7.30% | 8.16% | 8.54% | 10.52% | 7.03% |
Effective Tax Rate | 33.00% | 17.48% | 24.33% | 26.01% | 47.09% | 54.71% |
Revenue as Reported | 109.49 | 113.11 | 110.93 | 95.56 | 79.62 | 65.32 |